Analysts/Institutional Investor Meet/Con. Call Updates

August 17, 2026 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai- 400051 R ef: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Transcript of the conference call on the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 held on August 11, 2026. In continuation of our disclosures dated August 4, 2026 and August 11, 2026 and pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), the transcript of the conference call held on Tuesday, August 11, 2026 on the Un-audited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026 is enclosed herewith and is also available on the Company’s website at https://www.camlinfs.com/investor-relations/home/investor_call_recording. The Management was represented by Mr. Ashish Dandekar, Chairman & Managing Director, Mr. Nirmal Momaya, Managing Director and Mr. Santosh Parab, Chief Financial Officer. Discussions were based on publicly available information. No unpublished price sensitive information (UPSI) was discussed during the interactions. We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI Listing Regulations. Encl. a/a. Thanking You, For Camlin Fine Sciences Limited Rahul Sawale Company Secretary & VP Legal “Camlin Fine Sciences Limited Q1 FY27 Earnings Conference Call” August 11, 2026 “E&OE - This transcript is edited for factual errors and readability. In case of discrepancy, the audio recordings uploaded on the stock exchange on 11th August 2026 will prevail.” MANAGEMENT: MR. ASHISH DANDEKAR – CHAIRMAN AND MANAGING DIRECTOR – CAMLIN FINE SCIENCES LIMITED MR. NIRMAL MOMAYA – MANAGING DIRECTOR – CAMLIN FINE SCIENCES LIMITED MR. SANTOSH PARAB – CHIEF FINANCIAL OFFICER – CAMLIN FINE SCIENCES LIMITED Page 1 of 19 Camlin Fine Sciences Limited August 11, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Camlin Fine Sciences Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this call is being recorded. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. I now hand the conference over to the management for the opening remarks. Thank you, and over to you, sir. Ashish Dandekar: Ladies and gentlemen, welcome to the Earnings Conference Call. I'm Ashish Dandekar, Chairman and Managing Director; and with me are Nirmal Momaya, Managing Director; and Santosh Parab, our CFO. Since I know all of you are very busy, we will not waste time and get right into it. I hand over to Santosh for a brief on the earnings and the performance, following which we will take questions. Santosh Parab: Thank you, Ashish, and good evening to all the participants, and thank you for joining us. I'll quickly jump into the real business matter of today. Firstly, I'll just make a few announcements that you would have seen that we have changed our disclosures from the traditional lakhs and crores to million to match with the international standard. From this year, we have also started disclosing the segmental information. There is internal restructuring will happen and the management has started looking at the business in a more structured manner. And I think the investor community will be happy because this was always a request that it would be better understanding if we have segmental results. Coming down to overall revenues, our revenues were INR5,199 million. That's around 28% more as compared to the last year's quarter, and it's almost INR1,000 million more as compared to the last quarter. Obviously, we have done extremely well on the revenues, but the margins are not in line with the expectations, but there were certain reasons for that. The main reasons has been the raw material side where, as you know, the entire situation of raw material and the prices, the availability as well as the freight cost and other things have increased a lot. You would have seen the details of our financial statements and you would have seen that our margins, which were plus 45% last quarter, has come down to 4%, and that's what has percolated down to our EBITDA for the quarter. Coming down to the segments, as you could see, we have now segregated our business into 3 main verticals. The traditional, what we used to call straights and blends, which is now called as Page 2 of 19 Camlin Fine Sciences Limited August 11, 2026 Specialty Ingredients. This is a -- I say a nonchemical business. It's more of a knowledge business, which we sell blends to the end consumers. We have Aroma, the vanillin flavour fragrance business, that is manufacture of vanillin. And obviously, there is a third segment, which is Performance Chemicals, predominantly down- streams of our diphenol, which go to the product basket of straights and aroma. These are the other chemicals. All chemicals plants are in Performance Chemicals division, which transfer certain materials to the other 2 divisions for forward integration. And you would have seen the segmental results as an intersegment knockout in performance. These are nothing but the straights which are sold by Performance Chemicals as a chemical manufacturer to the Specialty Ingredients section; and raw material for Aroma, which is predominantly guaiacol, which is sold by Performance to Aroma at market prices or at the normal commercial terms based on arm's length principle. Specialty chemicals ingredient business sells straights as well as blends, as we used to show it in the earlier period. Coming down to the verticals, you would have seen that the straights business has been always growing and has better margins, and that has been also reflected in the numbers which we have disclosed. Straight sales has been around INR927 million, while Specialty Ingredient, that's the value- added blends, has been more than INR3,000 million, which is -- if you see on an overall basis, the Specialty Ingredient business has done more than INR4,000 million revenue. The EBITDA is 6.35% here. Predominantly, it has come down basically because of raw material prices being high. Coming down to Aroma, we have sold around 560 tons of vanillin in this quarter, which is primarily ethyl vanillin, which we took a campaign last year in the last quarter. We have sold around 200 metric tons of methyl vanillin, which were there in our channel stocks and internal channel stock. We have sold around 350 metric tons of ethyl vanillin in this quarter. Naturally, the capacity utilization was not optimal because we are taking such a large campaign of ethyl vanillin for the first time. We were cautious and the ramp-up was very cautiously done to get the qualities, to have the capacity utilization on the right track, understanding the dynamics of the new campaign. We are happy to announce that we have almost -- 95% of our customers have approved our ethyl vanillin. In this quarter, we have already sold 350. If you remember in last quarter, we have said that we are taking the campaign of 750-odd metric tons of ethyl vanillin. Half of that is done. We have produced almost more than 300 metric tons. We'll be taking a shutdown after the 750 ton ethyl vanillin campaigns over in mid of August, and then we switch to [Showing first 8,000 characters — download PDF for full document]